Picture supply: Getty Pictures
Airtel Africa (LSE: AAF) is the top-performing FTSE 100 inventory in my portfolio at present and it’s already gained an extra 10% this month.
One other certainly one of my favourites, albeit nowhere close to the highest, is GSK (LSE: GSK). After months of declines, the healthcare group has been making a restoration. It’s up a formidable 11.6% over the previous month.
They’re very completely different firms however each provide distinctive qualities, every serving to to bolster my portfolio in their very own manner.
An sudden progress alternative
As an investor who prefers the security of defensive revenue shares, Airtel Africa is an odd alternative for me. The telecoms supplier operates in what many would contemplate dangerous areas on the African continent.
Nevertheless, the chance has paid off. Up virtually 200% up to now yr, the inventory is outshining even the biggest S&P 500 tech giants in my portfolio.
Sadly, the expansion might not be sustainable. The current surge appears largely as a consequence of easing forex change pressures and tariff will increase in Nigeria. Those self same pressures might simply flip again within the different path in such a unstable area. That’s a key danger I have to keep watch over.
Nonetheless, sturdy financials are backing a number of the progress. Half-year income rose about 26% to almost $3bn, whereas revenue after tax climbed to $376m. With a quickly increasing community, rising margins and rising dividends, it appears to be heading in an excellent path.
The value could also be a bit overvalued now but it surely’s nonetheless value contemplating for its long-term prospects in Africa.
Resilient healthcare
GSK has recovered 38% after hitting a 52-week low on April’s commerce tariff information. It’s now only some pennies away from its five-year excessive of 1,800p achieved in Might 2024.
The biotechnology agency’s value was boosted by a powerful set of third-quarter outcomes and an improved outlook for 2025. The corporate reported gross sales of £8.5bn, up round 7% yr on yr, with notably sturdy efficiency from its Speciality Medicines division, which grew 16% to £3.4bn.
Its oncology gross sales had been a standout success, surging practically 39%. That shines a light-weight on the rising energy of its new drug portfolio after offloading its prescribed drugs arm.
The efficiency is supported by encouraging scientific updates, notably for its respiratory biologics and RSV vaccine.
However I didn’t purchase GSK shares for his or her progress prospects. They’re meant so as to add defensiveness to my portfolio, together with an honest little bit of revenue from the three.6% dividend yield.
Whereas the expansion is welcome, historical past exhibits that the inventory is extremely cyclical and can possible dip once more within the coming yr. Nonetheless, for revenue and defensiveness, it’s a worthy consideration, in my e-book.
Remaining ideas
It’s inconceivable to precisely predict the path of shares. At occasions, I’ve been pleasantly stunned, at others, I’ve been sadly dissatisfied.
That’s why I keep a extremely diversified portfolio of shares from a variety of industries. These two have completed effectively this month however might simply slip within the subsequent.
Nevertheless, general, my portfolio sometimes enjoys regular progress as every sector and inventory performs its half.
